OrthoSera launches BoneAlbumin for musculoskeletal indications

After a series of clinical studies showed positive effects of the patented albumin coating technology, there was a strong demand among physicians to use this graft.

The field of bone grafts is among the most promising markets in the orthopedic industry, generating more than 2 bn USD revenues globally and capturing an ever growing segment of the total orthobiologics market. The majority of bone substitutes are used in orthopedics and spine surgery while the dental field offers an additional opportunity with uniform dosing and self-paying customers. In order to capture this market opportunity OrthoSera launched a dental subsidiary with independent management and financing.

The Hungarian institutional investor Széchenyi Capital Investment Fund invested in OrthoSera Dental in exchange for a minority stake in the company. József Török, BizDev and Startup Director at the Fund comments: “Hungary is the leading global destination for dental tourism. Our investment enables the successful establishment of a fully human alternative to existing bone graft solutions in this segment further adding to the competitive advantage of regional dentists and implantologists.”

"Upon market entry with BoneAlbumin as our first commercial product we could convince a strong financing partner to join forces in setting up a fully-funded new entity. This is reflecting our transition to a commercial-stage company with additional exciting projects in the development pipeline. We felt that this is the perfect time to transform into OrthoSera," stresses Dr Zsombor Lacza, CEO of OrthoSera GmbH. "We expect to reach more significant milestones in the near future further underscoring our ambition to become a leading player in orthobiologics."